Oxford Biomedica is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases.

 

Background

  • Long-term advisor since 2003
  • World leading gene and cell therapy group and FTSE250 constituent of LSE’s Main Market

 

Strategy

  • Day to day strategic advice, sounding board and positioning of investment case including multiple deals, significant newsflow, financial results and financing rounds.
  • Major events included a $227 million agreement with Juno Therapeutics, a Bristol-Myers Squibb company, and OXB’s involvement in the development and supply of the AstraZeneca / Oxford COVID-19 vaccine candidate

 

Outcome

  • Positioned investment case across transactions in line with strategy
  • High quality and strategically placed coverage across business and investor media
  • Strong analyst support including initiation from US analyst
  • Upgraded shareholder base and increased awareness with international investors